Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.60 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | VEGFA | P15692 | 4/20 | 0.52 |
| ▸ | TET3 | O43151 | 1/20 | 0.52 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.52 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.52 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25930999 | 1.00 | EGLN1 (0.60) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL25930317 | 0.89 | EGLN1 (0.70) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL31204213 | 0.89 | EGLN1 (0.70) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL25930794 | 0.88 | EGLN1 (0.60) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL31204216 | 0.88 | EGLN1 (0.60) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL25930882 | 0.88 | EGLN1 (0.60) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL31203957 | 0.88 | EGLN1 (0.75) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL31204167 | 0.88 | EGLN1 (0.60) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL25930804 | 0.88 | EGLN1 (0.75) | EGLN1EGLN3FTOFLT1VEGFA | |
| SCHEMBL25930887 | 0.87 | EGLN1 (0.57) | EGLN1EGLN3FTOFLT1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376089-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376089-A1 | 3-HYDROXY-5-(ISOXAZOL-5-YL) PYRIDINE FORMYLGLYCINE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | HIF1AN, HIF1A, EGLN3 | EGLN1 5/4885EGLN3 3/4885FTO 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.